DPP4 and pancreatitis: While 100 mg sitagliptin could suppress 97% of DPP-4 for up to 24 h, its effects on hepatic cytochrome P450 enzymes were relatively weak and its pharmacokinetic characteristics remain unaffected when used in conjunction with other hypoglycemic drugs (e.g., metformin).17 A therapeutic dose of sitagliptin (100 mg/d) does not increase the risk of malignancy or pancreatitis,18 nor will it cause gastrointestinal reactions,4 which is in accordance with our data of reduced gas production in the experimental group.